CITER Research Workshop: Biomaterials: From Bench to Bedside

This event has ended.

The aim of this half-day workshop is to help academics translate their biomaterial technologies into the clinic for patient benefit. The objectives are to:

1. Gain insight into the regulatory pathway of biomaterials
2. Learn about a range of GLP pre-clinical models to demonstrate safety and efficacy of biomaterials
3. Understand the process of developing and registering a clinical trial for a biomaterial
4. Become familiar with funding routes and support to translate biomaterials into the clinic
5. Hear first-hand experiences from academics who have commercialised/translated biomaterials

The event is free to members of CITER and CMRN and will run from 12pm-5pm on Wednesday 27th November 2019 (a buffet lunch will be served between 12:00 – 13:00). The event will host a range of speakers, consisting of regulatory experts, pre-clinical testing specialists, clinical trials co-ordinators, funding advisors, academics and industry with examples of biomaterial technologies in pre-clinical and clinical stages. Following the workshop there will be networking opportunity between 17:00 – 18:00 with drinks.

Programme (subject to change)

12:00-13:00 Registration and lunch

Session 1: Pre-clinical development (Chair: Dr Wayne Nishio Ayre)

13:00-13:20 Dr Pete Wall (ISCA Healthcare Research) – Regulatory pathway

13:20-13:40 Ms Ryaka Poonawala (Medicines and Healthcare products Regulatory Agency) – Conformity assessment, the CE mark and off-label use

13:40-14:00 Dr Peter Rees (Covance) – Pre-clinical testing and models

14:00-14:15 Dr Ben Newland (Cardiff University) – Nanoscale and Microscale Biomaterials for Applications in Focal Drug Delivery

14:15-14:30 Dr Wayne Nishio Ayre (Cardiff University) – Commercialising bone cement: Lessons learned

14:30-15:00 Coffee break and networking

Session 2: Clinical development and funding pathways (Chair: Prof Jean-Yves Maillard)

15:00-16:00 Keynote speaker: Dr Michele Barbour (University of Bristol/Pertinax Pharma Ltd.) - Does it ever stop spinning?: One academic's reflections on research commercialisation and founding a biomedical spin-out company

16:00-16:15 Ms Rhian North (Research and Innovation Services) – Pre-clinical and clinical funding

16:15-16:30 Dr Corrine Nguyen (Accelerate) - Clinical Innovation Accelerator

16:30-16:45 Professor Chris Fegan/Mr Robyn Davies (Cardiff and Vale University Health Board) - Research and Development Support

16:45-17:00 Dr Philip Pallman (Centre for Trials Research) - Research Design and Conduct Service (RDCS)

17:00-18:00 Drinks reception and networking

Keynote speaker

Keynote speaker: Dr Michele Barbour (University of Bristol/Pertinax Pharma Ltd)

Does it ever stop spinning?: One academic's reflections on research commercialisation and founding a biomedical spin-out company

Dr Michele Barbour is a Reader in Biomaterials at the University of Bristol, and Deputy Head of Bristol Dental School where she leads the Oral Nanoscience Group. The Group's primary research interests are the development, characterisation and application of antimicrobial and antifouling nanoparticles and nanofilms for use in biomedical and consumer materials. She has over 50 publications in leading research journals and has co-authored several book chapters. As well as her academic role, Dr Barbour is the founder and CEO of Pertinax Pharma Ltd. Pertinax Pharma was founded as a spin-out of the University of Bristol to commercialise novel antimicrobial materials developed in Dr Barbour’s group. These materials are based on a common antiseptic, chlorhexidine, and can be used as a functional component of many different medical devices to deliver sustained protection against infection. The technology is the subject of several patent applications and its development has been is supported by research council and Innovate UK funding as well as equity-based investment. Dr Barbour’s lecture will focus on the research that led to the formation of Pertinax, and to the journey since spinning out.